3-iodobenzylguanidine has been researched along with metformin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Inoue, K; Ito, S; Kusuhara, H; Sugiyama, Y; Toyoshima, J; Yokochi, M; Yuasa, H | 1 |
| Hsiao, R; Ikegaki, N; Limpar, MM; Lomahan, S; Maloney, NJ; Tang, XX; Tran, TA; Wang, SS | 1 |
2 other study(ies) available for 3-iodobenzylguanidine and metformin
| Article | Year |
|---|---|
Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney.
Topics: 1-Methyl-4-phenylpyridinium; 3-Iodobenzylguanidine; Animals; Binding, Competitive; Biological Transport; Cephalexin; Cimetidine; Dose-Response Relationship, Drug; Drug Interactions; HEK293 Cells; Humans; Kidney; Kinetics; Liver; Male; Metformin; Mice; Mice, Inbred Strains; Organic Cation Transport Proteins; Organic Cation Transporter 1; Organic Cation Transporter 2; Pyridines; Tetraethylammonium; Transfection | 2012 |
Destabilization of MYC/MYCN by the mitochondrial inhibitors, metaiodobenzylguanidine, metformin and phenformin.
Topics: 3-Iodobenzylguanidine; Acetylation; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Metformin; Mitochondria; N-Myc Proto-Oncogene Protein; Neuroblastoma; Nuclear Proteins; Oncogene Proteins; Phenformin; Proto-Oncogene Proteins c-myc; Up-Regulation | 2014 |